Crossroads Behavioral Health, P.l.c. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 218 Allegheny Ave, Suite 101, Wabasha, MN 55981 Phone: 651-560-7103 |
Wenden Recovery Services Of Wabasha Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 218 Main St W, Wabasha, MN 55981 Phone: 651-565-5400 Fax: 651-565-5404 |
Cosan Leighis Llc Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 145 2nd St W, Wabasha, MN 55981 Phone: 715-279-8591 |
Jonathan G. Peterson Psychiatry, Ltd. Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 207 Hiawatha Dr E, Wabasha, MN 55981 Phone: 651-564-1545 |
Hiawatha Valley Mental Health Center Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 611 Broadway Ave, Suite 100, Wabasha, MN 55981 Phone: 651-565-2234 |
News Archive
Two products from Prescient Medical - the vProtect(TM) Luminal Shield and the vPredict(TM) Optical Catheter System - will be featured at the 3rd Annual Canaccord Adams Cardiovascular Conference. The conference will take place on Tuesday, November 10th in San Francisco, California, and will bring together a select group of med-tech and biotech companies focused on the most important markets in cardiovascular medicine.
A person's skin and a fruit fly's exoskeleton, called a "cuticle" may not look alike, but both coverings protect against injury, infection, and dehydration.
A research group at the Center for iPS Cell Research and Application (CiRA) at Japan's Kyoto University has successfully recapitulated amyotrophic lateral sclerosis (ALS)-associated abnormalities in motor neurons differentiated from induced pluripotent stem cells (iPSCs) obtained from patients with familial ALS, a late-onset, fatal disorder which is also known for Lou Gehrig's disease. In a drug screening assay using the disease model, the team further found that the chemical compound anacardic acid can rescue some ALS phenotypes in vitro.
New preclinical work by a team of researchers from Roswell Park Comprehensive Cancer Center's Transplant and Cellular Therapy Program suggests that the risk of developing acute graft vs. host disease during allogeneic blood/marrow transplant - a potentially curative treatment for selected patients with hematologic disorders -; can be decreased using an existing class of drugs called beta adrenergic agonists.
› Verified 7 days ago